Blood-based Genomic and Cellular Determinants of Response to Neoadjuvant PD-1 Blockade in Patients with Non-Small-Cell Lung Cancer

The integrated analyses employed in the current study identified blood-based molecular and cellular signatures that are associated with the responsiveness and overall survival of PD-1/PD-L1 blockade therapy plus chemotherapy. Comparative gene expression profiling analysis of RNA Seq data for 57 whole blood samples from 31 NSCLC patients and 5 healthy donors, including both responders and non-responders received anti-PD-1 Tislelizumab plus chemotherapy.